Pharmadrug Stock Net Income

LMLLF Stock  USD 0.01  0  62.67%   
Pharmadrug fundamentals help investors to digest information that contributes to Pharmadrug's financial success or failures. It also enables traders to predict the movement of Pharmadrug Pink Sheet. The fundamental analysis module provides a way to measure Pharmadrug's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmadrug pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pharmadrug Company Net Income Analysis

Pharmadrug's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Pharmadrug Net Income

    
  (5.63 M)  
Most of Pharmadrug's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmadrug is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, Pharmadrug reported net income of (5.63 Million). This is 101.65% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.99% higher than that of the company.

Pharmadrug Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmadrug's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharmadrug could also be used in its relative valuation, which is a method of valuing Pharmadrug by comparing valuation metrics of similar companies.
Pharmadrug is currently under evaluation in net income category among its peers.

Pharmadrug Fundamentals

About Pharmadrug Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pharmadrug's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmadrug using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmadrug based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Pharmadrug Pink Sheet

Pharmadrug financial ratios help investors to determine whether Pharmadrug Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmadrug with respect to the benefits of owning Pharmadrug security.